Author Of 1 Presentation
P0258 - MS Progression Discussion Tool (MSProDiscuss™) Usability and Usefulness Assessment in Clinical Practice in Chile. (ID 568)
Abstract
Background
Multiple Sclerosis (MS) is the most common chronic immune-mediated and neurodegenerative disease of the Central Nervous System, affecting around 2.3 million people worldwide. Approximately 25-40% of patients will transition to SPMS within 10 years of MS onset. Defining the transition from RRMS to SPMS can be challenging and may result in delayed diagnosis and impact treatment decision making. MSProDiscuss™ is a freely available educational tool developed and validated to facilitate physician-patient discussion on subtle early signs of MS progression and enable patient-HCP conversation.
Objectives
Evaluate the usefulness and usability of the MSProDiscuss™ clinician-completed tool in clinical practice in Chile.
Methods
Eight neurologists were consulted on feedback for MSProDiscuss™ implementation into daily clinical practice. The physician entered details of patient disease activity, symptoms and their impact experienced in the last six months. After completion, a traffic-light output displayed the level of progression. After that, physicians completed questionnaires about understanding, usefulness, usability and integration/adoption of the tool into daily clinical practice.
Results
The tool was implemented during 275 MS patient medical appointments. All neurologists indicated that the time to complete the tool was satisfactory, 96.8% said that patients well-understood the questions and 93.5% agreed that the traffic light colors helped to discuss MS progression. In addition, regarding the discussion of MS progression symptoms, and their impact on daily activities and on cognitive functions, 89.7% and 80.2% referred that the tool helped to discuss them, respectively. Lastly, 98.9% would use the tool with patients in the future.
Conclusions
Neurologists indicated that MSProDiscuss™ was very useful for evaluating and consulting about the MS progression and its impact on daily life. According to their feedback, it provided an idea of the degree of disability and transition to SPMS. Besides, it facilitated an informed doctor-patient discussion.
Presenter Of 1 Presentation
P0258 - MS Progression Discussion Tool (MSProDiscuss™) Usability and Usefulness Assessment in Clinical Practice in Chile. (ID 568)
Abstract
Background
Multiple Sclerosis (MS) is the most common chronic immune-mediated and neurodegenerative disease of the Central Nervous System, affecting around 2.3 million people worldwide. Approximately 25-40% of patients will transition to SPMS within 10 years of MS onset. Defining the transition from RRMS to SPMS can be challenging and may result in delayed diagnosis and impact treatment decision making. MSProDiscuss™ is a freely available educational tool developed and validated to facilitate physician-patient discussion on subtle early signs of MS progression and enable patient-HCP conversation.
Objectives
Evaluate the usefulness and usability of the MSProDiscuss™ clinician-completed tool in clinical practice in Chile.
Methods
Eight neurologists were consulted on feedback for MSProDiscuss™ implementation into daily clinical practice. The physician entered details of patient disease activity, symptoms and their impact experienced in the last six months. After completion, a traffic-light output displayed the level of progression. After that, physicians completed questionnaires about understanding, usefulness, usability and integration/adoption of the tool into daily clinical practice.
Results
The tool was implemented during 275 MS patient medical appointments. All neurologists indicated that the time to complete the tool was satisfactory, 96.8% said that patients well-understood the questions and 93.5% agreed that the traffic light colors helped to discuss MS progression. In addition, regarding the discussion of MS progression symptoms, and their impact on daily activities and on cognitive functions, 89.7% and 80.2% referred that the tool helped to discuss them, respectively. Lastly, 98.9% would use the tool with patients in the future.
Conclusions
Neurologists indicated that MSProDiscuss™ was very useful for evaluating and consulting about the MS progression and its impact on daily life. According to their feedback, it provided an idea of the degree of disability and transition to SPMS. Besides, it facilitated an informed doctor-patient discussion.